File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: PET/Computed Tomography Transformation of Oncology

TitlePET/Computed Tomography Transformation of Oncology
Authors
Lee, Elaine Yuen PhinIp, Pun Ching PhilipTse, Ka YuKwok, Shuk TakChiu, Wan KamHo, Grace
KeywordsCytoreduction
Disease staging
FDG
Ovarian cancer
PET/CT
Recurrence detection
Issue Date1-Apr-2024
PublisherElsevier
Citation
PET Clinics, 2024, v. 19, n. 2, p. 207-216 How to Cite?
DOI: http://dx.doi.org/10.1016/j.cpet.2023.12.007
Abstract

Over the last quarter of a century, fluorine-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) has revolutionized the diagnostic algorithm of ovarian cancer, impacting on the initial disease evaluation including staging and surgical planning, treatment response assessment and prognostication, to the most important role in detection of recurrent disease. The role of FDG PET/CT is expanding with the adoption of new therapeutic agents. Other non-FDG tracers have been explored with fibroblast activation protein inhibitor being promising. Novel tracers may provide the basis for future theragnostic work. This article will review the evolution and impact of PET/CT in ovarian cancer management.


Persistent Identifierhttp://hdl.handle.net/10722/342856
ISSN
1556-8598
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.997

 

DC FieldValueLanguage
dc.contributor.authorLee, Elaine Yuen Phin-
dc.contributor.authorIp, Pun Ching Philip-
dc.contributor.authorTse, Ka Yu-
dc.contributor.authorKwok, Shuk Tak-
dc.contributor.authorChiu, Wan Kam-
dc.contributor.authorHo, Grace-
dc.date.accessioned2024-05-02T03:06:23Z-
dc.date.available2024-05-02T03:06:23Z-
dc.date.issued2024-04-01-
dc.identifier.citationPET Clinics, 2024, v. 19, n. 2, p. 207-216-
dc.identifier.issn1556-8598-
dc.identifier.urihttp://hdl.handle.net/10722/342856-
dc.description.abstract<p>Over the last quarter of a century, fluorine-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) has revolutionized the diagnostic algorithm of ovarian cancer, impacting on the initial disease evaluation including staging and surgical planning, treatment response assessment and prognostication, to the most important role in detection of recurrent disease. The role of FDG PET/CT is expanding with the adoption of new therapeutic agents. Other non-FDG tracers have been explored with fibroblast activation protein inhibitor being promising. Novel tracers may provide the basis for future theragnostic work. This article will review the evolution and impact of PET/CT in ovarian cancer management.<br></p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofPET Clinics-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCytoreduction-
dc.subjectDisease staging-
dc.subjectFDG-
dc.subjectOvarian cancer-
dc.subjectPET/CT-
dc.subjectRecurrence detection-
dc.titlePET/Computed Tomography Transformation of Oncology-
dc.typeArticle-
dc.identifier.doi10.1016/j.cpet.2023.12.007-
dc.identifier.scopuseid_2-s2.0-85184678614-
dc.identifier.volume19-
dc.identifier.issue2-
dc.identifier.spage207-
dc.identifier.epage216-
dc.identifier.eissn1879-9809-
dc.identifier.issnl1556-8598-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats